# Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer

> **NCT01577654** · PHASE2 · COMPLETED · sponsor: **Endocyte** · enrollment: 203 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** EC145
- **DRUG:** EC145 + Docetaxel
- **DRUG:** Docetaxel
- **DRUG:** EC20

## Key facts

- **NCT ID:** NCT01577654
- **Lead sponsor:** Endocyte
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-12
- **Final completion:** 2015-08
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01577654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01577654, "Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01577654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*